Zeria Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Zeria Pharmaceutical has been growing earnings at an average annual rate of 26.9%, while the Pharmaceuticals industry saw earnings growing at 3.4% annually. Revenues have been growing at an average rate of 5.7% per year. Zeria Pharmaceutical's return on equity is 11%, and it has net margins of 11.4%.
Belangrijke informatie
26.9%
Groei van de winst
28.5%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 3.4% |
| Inkomstengroei | 5.7% |
| Rendement op eigen vermogen | 11.0% |
| Nettomarge | 11.4% |
| Volgende winstupdate | 06 Nov 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Zeria Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 78,876 | 9,028 | 38,113 | 3,726 |
| 31 Mar 24 | 75,725 | 7,731 | 36,834 | 3,726 |
| 31 Dec 23 | 74,573 | 8,638 | 37,328 | 3,456 |
| 30 Sep 23 | 71,349 | 7,593 | 35,924 | 3,456 |
| 30 Jun 23 | 70,382 | 6,509 | 34,631 | 3,456 |
| 31 Mar 23 | 68,383 | 6,195 | 32,646 | 3,456 |
| 31 Dec 22 | 66,157 | 5,898 | 33,362 | 4,789 |
| 30 Sep 22 | 64,638 | 5,844 | 31,964 | 4,789 |
| 30 Jun 22 | 62,289 | 5,154 | 31,721 | 4,789 |
| 31 Mar 22 | 59,532 | 3,961 | 30,993 | 4,789 |
| 31 Dec 21 | 58,172 | 3,476 | 30,521 | 5,411 |
| 30 Sep 21 | 57,239 | 3,846 | 30,693 | 5,411 |
| 30 Jun 21 | 55,659 | 3,553 | 30,431 | 5,411 |
| 31 Mar 21 | 55,442 | 3,119 | 30,781 | 5,411 |
| 31 Dec 20 | 56,497 | 4,272 | 29,789 | 6,342 |
| 30 Sep 20 | 56,918 | 3,083 | 30,893 | 6,342 |
| 30 Jun 20 | 58,644 | 2,753 | 32,324 | 6,342 |
| 31 Mar 20 | 60,426 | 2,925 | 33,439 | 6,342 |
| 31 Dec 19 | 60,919 | 2,893 | 33,034 | 6,832 |
| 30 Sep 19 | 61,665 | 2,404 | 34,025 | 6,832 |
| 30 Jun 19 | 61,685 | 2,356 | 33,759 | 6,832 |
| 31 Mar 19 | 61,831 | 3,454 | 33,502 | 6,832 |
| 31 Dec 18 | 62,139 | 3,102 | 33,833 | 7,331 |
| 30 Sep 18 | 62,639 | 4,309 | 33,109 | 7,331 |
| 30 Jun 18 | 63,857 | 5,744 | 32,718 | 7,331 |
| 31 Mar 18 | 64,568 | 4,157 | 34,074 | 7,331 |
| 31 Dec 17 | 65,450 | 4,626 | 32,782 | 8,458 |
| 30 Sep 17 | 64,948 | 3,666 | 33,939 | 8,458 |
| 30 Jun 17 | 64,331 | 2,873 | 33,819 | 8,458 |
| 31 Mar 17 | 64,849 | 3,544 | 33,691 | 8,458 |
| 31 Dec 16 | 64,464 | 3,051 | 33,545 | 8,579 |
| 30 Sep 16 | 64,445 | 3,903 | 32,390 | 8,579 |
| 30 Jun 16 | 64,238 | 3,950 | 32,823 | 8,579 |
| 31 Mar 16 | 62,475 | 3,513 | 31,403 | 8,579 |
| 31 Dec 15 | 62,284 | 2,732 | 31,192 | 9,882 |
| 30 Sep 15 | 61,219 | 2,058 | 30,860 | 9,882 |
| 30 Jun 15 | 61,022 | 2,400 | 30,002 | 9,882 |
| 31 Mar 15 | 61,012 | 2,557 | 29,979 | 9,882 |
| 31 Dec 14 | 61,005 | 3,866 | 30,607 | 7,464 |
| 30 Sep 14 | 62,023 | 4,056 | 30,577 | 7,464 |
| 30 Jun 14 | 61,371 | 3,890 | 30,108 | 7,464 |
| 31 Mar 14 | 61,996 | 5,277 | 29,390 | 7,464 |
| 31 Dec 13 | 59,791 | 5,276 | 29,488 | 5,629 |
Kwaliteitswinsten: 4559 has high quality earnings.
Groeiende winstmarge: 4559's current net profit margins (11.4%) are higher than last year (9.2%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 4559's earnings have grown significantly by 26.9% per year over the past 5 years.
Versnelling van de groei: 4559's earnings growth over the past year (38.7%) exceeds its 5-year average (26.9% per year).
Winst versus industrie: 4559 earnings growth over the past year (38.7%) exceeded the Pharmaceuticals industry 38.7%.
Rendement op eigen vermogen
Hoge ROE: 4559's Return on Equity (11%) is considered low.